Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Erica S. Tsang, Qian Shi, Ken Olive, Eric Collisson, Jesse G. Dixon, Mike Cusnir, Rafael Winograd, Gregory P. Botta, Raymond Wadlow, Ardaman Shergill, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, Andrew H. Ko

Open source

DOI: 10.1200/oa-25-00099
Published: 2025-10
Container: JCO Oncology Advances
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/oa-25-00099,
  title = {Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for
                    <i>BRCA1/2</i>
                    or
                    <i>PALB2</i>
                    Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)},
  author = {Erica S. Tsang and Qian Shi and Ken Olive and Eric Collisson and Jesse G. Dixon and Mike Cusnir and Rafael Winograd and Gregory P. Botta and Raymond Wadlow and Ardaman Shergill and Jeffrey A. Meyerhardt and Eileen M. O'Reilly and Andrew H. Ko},
  year = {2025},
  journal = {JCO Oncology Advances},
  doi = {10.1200/oa-25-00099},
  url = {https://doi.org/10.1200/oa-25-00099}
}

RIS

TY  - JOUR
TI  - Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for
                    <i>BRCA1/2</i>
                    or
                    <i>PALB2</i>
                    Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
AU  - Erica S. Tsang
AU  - Qian Shi
AU  - Ken Olive
AU  - Eric Collisson
AU  - Jesse G. Dixon
AU  - Mike Cusnir
AU  - Rafael Winograd
AU  - Gregory P. Botta
AU  - Raymond Wadlow
AU  - Ardaman Shergill
AU  - Jeffrey A. Meyerhardt
AU  - Eileen M. O'Reilly
AU  - Andrew H. Ko
PY  - 2025
JO  - JCO Oncology Advances
DO  - 10.1200/oa-25-00099
UR  - https://doi.org/10.1200/oa-25-00099
ER  -

APA

Tsang, E. S., Shi, Q., Olive, K., Collisson, E., Dixon, J. G., Cusnir, M., Winograd, R., Botta, G. P., Wadlow, R., Shergill, A., Meyerhardt, J. A., O'Reilly, E. M., & Ko, A. H. (2025). Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM). JCO Oncology Advances. https://doi.org/10.1200/oa-25-00099

Source records

crossref · retrieved 2026-09-25T06:43:45.842Z

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for <i>BRCA1/2</i> or <i>PALB2</i> Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records